Skip to main content

Table 2 Association of CDKN2A methylation and clinico-pathological features in colorectal cancers (n = 422)

From: Characterization of CDKN2A(p16) methylation and impact in colorectal cancer: systematic analysis using pyrosequencing

Feature   CDKN2A N(%) P-value
   Negative (335; 79.4%) Methylated (87; 20.6%)  
Age Mean (range) 69.3 (37–95) 68.8 (39–89) 0.7292
Tumor size Mean (range) 49.3 (5–160) 53.5 (4–170) 0.1265
Tumor location Left-sided 232 (69.5) 40 (46.5) <0.0001
  Right-sided 102 (30.5) 46 (53.5)  
Gender Female 181 (54.0) 48 (55.2) 0.849
  Male 154 (46.0) 39 (44.8)  
Histological subtype Non-mucinous 19 (5.7) 11 (12.6) 0.0209
  Mucinous 316 (94.3) 76 (87.4)  
Tumor grade G1-2 317 (96.7) 74 (85.1) <0.0001
  G3 11 (3.4) 13 (14.9)  
pT classification pT1-2 75 (22.9) 14 (16.1) 0.1711
  pT3-4 253 (77.1) 73 (83.9)  
pN classification pN0 180 (55.9) 37 (43.0) 0.0335
  pN1-2 142 (44.1) 49 (57.0)  
Vascular invasion Absent 238 (72.6) 54 (62.1) 0.0568
  Present 90 (27.4) 33 (37.9)  
Invasive margin Pushing 101 (30.9) 21 (24.4) 0.242
  Infiltrating 226 (69.1) 65 (75.6)  
Peritumoral lymphocytic inflammation Absent 251 (76.5) 66 (75.9) 0.897
  Present 77 (23.5) 21 (24.1)  
KRAS (codon 12/13) Wild-type 227 (69.2) 58 (72.5) 0.565
  Mutation 101 (30.8) 22 (27.5)  
BRAF (codon V600E) Wild-type 287 (94.1) 53 (68.8) <0.0001
  Mutation 18 (5.9) 24 (31.2)  
MSI status MSS/MSI-L 272 (86.6) 62 (76.5) 0.0252
  MSI-H 42 (13.4) 19 (23.5)